CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2-Reference-Cited by-同舟云学术

CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2

Published:2005-03 Issue:2 Volume:28 Page:120-128
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Antony Paul Andrew,Restifo Nicholas P

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference98 articles.

1. Selective in vitro growth of T lymphocytes from normal human bone marrows.;Morgan;Science,1976

2. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor.;Sharfe;Proc Natl Acad Sci USA,1997

3. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers.;Almeida;J Immunol,2002

4. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity.;Belkaid;Nature,2002

5. CD4(+)CD25(+) T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells.;Suri-Payer;J Immunol,1998

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non‐IL‐2‐blocking anti‐CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti‐CTLA‐4 therapy;International Journal of Cancer;2024-01-05

2. Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?;Frontiers in Immunology;2023-11-22

3. Efficient T cell adoptive transfer in lymphoreplete hosts mediated by transient activation of Stat5 signaling;Molecular Therapy;2023-09

4. ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer;Future Oncology;2023-07

5. NL-201 Upregulates MHC-I Expression and Intratumoral T-cell Receptor Diversity, and Demonstrates Robust Antitumor Activity as Monotherapy and in Combination with PD-1 Blockade;Cancer Immunology Research;2023-05-02